CORONA Remedies Peer Comparison

NSE: CORONA | BSE: 544644

₹2,100.10

₹-27.70 (-1.30%)

As on 04-Sep-2026 15:56IST

Market cap

₹12,843 Cr

Revenue (TTM)

₹1,479 Cr

P/E Ratio

64.5

P/B Ratio

15.9

Div. Yield

0.5 %

Edit

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Market cap (₹ Cr)	12,843	21,361	21,107	18,873	18,390
Revenue (₹ Cr)	1,479	2,287	2,570	1,682	3,230
Net Profit (₹ Cr)	198.55	678.07	735.15	273.51	666.92
Net Margin (%)	13.32	28.10	26.88	16.19	20.60
RoE (%)	30.33	19.73	19.16	11.15	18.75
Price to Earnings	64.53	32.11	28.71	63.48	28.56
Price-To-Book	15.92	5.82	4.79	7.03	4.56

Income Statement (₹ Cr)

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Operating Revenue	1,479.07	2,287.33	2,569.77	1,682.47	3,229.67
Total Income	1,490.84	2,413.29	2,735.39	1,689.83	3,237.12
Total Expenditure	1,162.29	1,490.75	1,628.14	1,203.91	2,090.06
EBITDA	316.78	796.58	941.63	478.55	1,139.61
Depreciation	42.18	78.10	57.58	126.01	281.06
EBIT	274.60	718.48	884.05	352.55	858.55
Interest	7.66	0.88	7.69	52.11	190.64
Other Income	11.77	125.96	165.62	7.37	7.45
Exceptional Items	-19.10	0.00	-49.16	12.16	-17.24
Profit before Tax	259.61	843.56	992.82	319.96	658.12
Provision for Tax	61.06	165.49	257.67	46.45	-8.80
Profit after Tax	198.55	678.07	735.15	273.51	666.92

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Shareholder's Funds	745.97	3,586.42	4,202.90	2,591.20	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	97.11	28.74	91.50	266.35	1,392.75
Current Liabilities	361.17	385.94	627.48	848.06	2,077.10
Total Liabilities	--	4,037.51	4,921.88	3,705.61	7,246.72

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Non-Current Assets	722.50	1,291.22	770.28	2,525.44	5,617.77
Current Assets	348.31	2,585.66	3,803.22	1,109.77	1,539.85
Total Assets	--	4,037.51	4,921.88	3,705.61	7,246.72
Total Debt*	--	0.57	2.50	657.97	2,309.68
Net Current Assets	-12.86	2,199.72	3,175.74	261.71	-537.25
Contingent Liabilities	--	17.53	370.49	160.01	51.57

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Cash From Operating Activities	--	523.24	967.57	342.18	537.99
Cash Flow from Investing Activities	--	-582.30	-561.67	-325.92	-369.46
Cash from Financing Activities	--	-46.46	-798.31	13.62	-313.53
Net Cash Inflow / Outflow	--	-105.52	-392.41	29.88	-145.00

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
ROCE (%)	--	24.97	23.39	11.43	14.47
ROE (%)	30.29	19.73	19.16	11.15	18.75
ROA (%)	32.97	18.69	14.95	7.80	9.26
EBIT Margin (%)	18.57	31.41	34.40	20.95	26.58
Net Margin (%)	13.32	28.10	26.88	16.19	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Revenue Growth (%)	18.16	15.01	10.69	27.91	9.59
EBIT Growth (%)	23.39	18.45	24.14	58.32	16.84
Net Profit Growth (%)	19.98	19.61	-9.09	149.56	62.68
EPS Growth (%)	28.60	17.73	14.40	-3.57	67.41
Book Value Growth (%)	--	26.75	-0.34	9.67	36.71

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Price / Earnings	60.35	32.11	27.36	67.34	27.87
Price / Book Value	15.93	5.82	4.79	7.03	4.56
Dividend Yield (%)	0.48	0.28	1.63	0.06	0.00
EV/EBITDA	40.85	25.55	19.11	40.72	18.10
Market Cap (₹ Cr)	--	11,439.22	21,592.90	6,819.66	17,980.08

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Debt to Equity	0.00	0.00	0.00	0.07	0.24
Short term debt to equity ratio	--	0.00	0.00	0.16	0.12
Current Ratio	0.96	6.70	6.06	1.31	0.74
Quick Ratio	0.62	5.59	5.31	0.88	0.53
Interest Coverage	34.89	959.59	130.11	7.14	4.45

	CORONA Remedies	Caplin Point Lab	Pfizer	Shilpa Medicare	Eris Lifesciences
Debtors to sales (%)	9.84	36.10	7.07	30.84	21.07
Asset Turnover	2.46	0.63	0.52	0.48	0.45
Receivable days	--	121.68	26.06	113.81	63.88
Inventory Days	--	63.83	65.95	84.76	43.27
Payable days	--	108.28	81.01	101.94	151.85
Cash Conversion Cycle	--	77.23	11.00	96.62	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.